PhaSER - Drug-Drug Interaction Modelling

Impact: Health and Welfare Impact, Economic, Commercial Impact

Description of impact

Adviser and consultant to PhaSER, a biotech company that will carry out mathematical modelling of drug-drug interactions (DDI) alongside 8HUM mouse validation.


PhaSER, was formed in 2022 from 8HUM technology developed by Taconic and the University of Dundee over a 20 year period. PhaSER is collaborating with multiple companies, universities and charitable organisations to ensure that the 8HUM mouse model is used as widely as possible in drug discovery and development applications.
Impact statusOpen
Category of impactHealth and Welfare Impact, Economic, Commercial Impact
Impact levelInvolvement - mid or active stage